ClinicalTrials.gg
RecruitingNCT07727642OPT-ARLUpdated Jul 27, 2026

Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma

An interventional study of Oral Antiretroviral Therapy and albuvirtide in AIDS-related Lymphoma and HIV Infection, sponsored by Shanghai Public Health Clinical Center. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Shanghai Public Health Clinical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of different antiretroviral therapy (ART) strategies in adults with AIDS-related lymphoma (ARL) receiving anti-lymphoma treatment. The main questions it aims to answer are:

Does long-acting injectable ART, including albuvirtide (ABT) or long-acting cabotegravir/rilpivirine (CAB/RPV), improve virological suppression compared with oral ART during anti-lymphoma treatment? Do different ART strategies differ in immune recovery, virological failure, low-level viremia, and safety in patients with ARL?

Researchers will compare three treatment strategies-oral ART alone, oral ART plus long-acting albuvirtide (ABT), and long-acting cabotegravir/rilpivirine (CAB/RPV)-to determine whether long-acting injectable ART provides better virological control and comparable safety during lymphoma treatment.

Participants will:

Receive one of three ART strategies according to their clinical condition and treatment preference while receiving standard anti-lymphoma therapy.

Attend scheduled study visits at baseline and Weeks 4, 8, 12, 24, 36, and 48. Undergo plasma HIV-1 RNA testing, CD4+ T-cell count measurement, laboratory assessments, and safety evaluations throughout the 48-week follow-up period.

Be monitored for virological suppression, immune recovery, adverse events, and lymphoma-related clinical outcomes.

02

Conditions studied

  • AIDS-related Lymphoma
  • HIV Infection

Keywords

  • HIV
  • AIDS-Related Lymphoma
  • Antiretroviral Therapy
  • Albuvirtide
  • Cabotegravir
  • Rilpivirine
  • Long-Acting Injectable ART
  • Virological Suppression
03

In context

Lymphoma, AIDS-Related

25 studies on the registry are indexed under Lymphoma, AIDS-Related; 2 are open to participants now.

This study's planned enrollment of 60 is above the median of 18 across 13 interventional studies indexed under Lymphoma, AIDS-Related.

Browse Lymphoma, AIDS-Related studies →

Lead sponsor

Shanghai Public Health Clinical Center is the lead sponsor of 38 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Age ≥18 years. Confirmed infection. confirmed AIDS-related lymphoma. Receiving anti-lymphoma treatment. Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

- Expected survival less than 6 months. Severe concomitant or uncontrolled comorbidity. Refusal to receive antiretroviral therapy or lymphoma treatment. to study medications. Inability to complete scheduled follow-up. Any condition considered unsuitable by the investigator.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Oral ART

    Participants will receive standard oral antiretroviral therapy throughout lymphoma treatment.

    Drug: Oral Antiretroviral Therapy

  • Other
    Oral ART Plus Albuvirtide

    Participants with viremia who agree to receive long-acting therapy will receive oral ART combined with intravenous albuvirtide.

    Drug: Oral Antiretroviral Therapy · Drug: albuvirtide

  • Other
    Long-Acting Cabotegravir/Rilpivirine

    Eligible participants will receive long-acting intramuscular cabotegravir and rilpivirine according to the approved dosing schedule.

    Drug: Cabotegravir/Rilpivirine

Interventions

  • DrugOral Antiretroviral Therapy

    Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) or Current Oral ART Regimen at lymphoma diagnosis

  • Albuvirtide 640 mg intravenously every 4 weeks for five doses.

  • DrugCabotegravir/Rilpivirine

    long-acting intramuscular cabotegravir and rilpivirine according to the approved dosing schedule.

06

What researchers measure

Primary outcomes

  1. Virological Suppression Rate at Week 24

    Percentage of participants achieving plasma HIV RNA \<50 copies/mL at Week 24.

    Time frame: Week 24

Secondary outcomes

  1. CD4 Cell Count Change

    Change from baseline in CD4+ T-cell count.

    Time frame: Week 24 Week 48

  2. Low-Level Viremia

    Percentage of participants with HIV RNA between 50 and 200 copies/mL.

    Time frame: Week 24 and Week 48

  3. Virological Failure

    Percentage of participants with HIV RNA ≥200 copies/mL.

    Time frame: Week 24

  4. Adverse Events

    Incidence of adverse events and serious adverse events.

    Time frame: Baseline through Week 48

  5. Virological Suppression Rate at Week 48

    Percentage of participants achieving plasma HIV RNA \<50 copies/mL at Week 48.

    Time frame: Week 48.

07

Study locations

1 of 1 sites recruiting
  • Shanghai Public Health Clinical Center
    Shanghai, Shanghai Municipality 201508, China
    Recruiting
08

References and documents

Publications

  • Sax PE, Thompson MA, Saag MS; IAS-USA Treatment Guidelines Panel. Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel. JAMA. 2024 Mar 26;331(12):1060-1061. doi: 10.1001/jama.2024.2985. No abstract available. PubMed 38427337 ↗
  • Fu Y, Xie X, Gan L, Yang X, Song Y, Song C, Sun F, Guo L, Long H. Safety, pharmacokinetics, and efficacy of albuvirtide administered by intravenous bolus every 4 weeks in combination with oral dolutegravir in virologically suppressed adults living with HIV: A 24-week study. Int J Infect Dis. 2026 Jan;162:108163. doi: 10.1016/j.ijid.2025.108163. Epub 2025 Oct 25. PubMed 41429707 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Jul 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 27, 2026
StartActual
May 26, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07727642
Lead sponsor
Shanghai Public Health Clinical Center
Responsible party
Zhenyan Wang (Associate Chief Physician, Shanghai Public Health Clinical Center) — Principal investigator
First posted
Jul 27, 2026
Start date
May 26, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jul 27, 2026

Study contacts

Zhenyan Wang
Contact
wangzhenyan@shaphc.org
+86021-37990333-3222

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion